arrow
S

Sergio Di Matteo

save studi
H指数:11
被引数:515

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy

与Teclistamab相比,Elranatamab在意大利用于管理三药类暴露的复发/难治性多发性骨髓瘤患者的成本效益。

Cancers
IF4.4
2026-04-030
OAAI
The SHARP CRC Health Economics Study. Simulation of the preventable costs of oral corticosteroids in severe asthmatics in eleven European countries
2024-10-300
PRE
Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
2019-01-0193
OAAI